PDF Cover

Vadadustat Market

Vadadustat Market

The market for Vadadustat was estimated at $766 million in 2024; it is anticipated to increase to $1.15 billion by 2030, with projections indicating growth to around $1.61 billion by 2035.

Report ID:DS1802563
Author:Debadatta Patel - Senior Consultant
Published Date:June 2025
Datatree
Life Science
Pharmaceutical
Vadadustat
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Vadadustat Market Outlook

Revenue, 2024

$766M

Forecast, 2034

$1.51B

CAGR, 2024 - 2034

7.0%
The Vadadustat industry revenue is expected to be around $819.9 million in 2025 and expected to showcase growth with 7.0% CAGR between 2025 and 2034. The steady growth in Vadadustat market underscores the drugs ongoing relevance in the healthcare industry. The market expansion is fuelled by key driving factors such as increasing prevalence of chronic kidney disease , enhanced focus on research and development, advancements in novel anemia therapies, and the persistent need for safer and more effective treatment options. Simultaneously, Vadadustats potential in addressing unmet medical needs and improving patient outcomes continue to support its prominence.

An overview of Vadadustat reveals it as an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate erythropoiesis. The drug is steadily gaining traction as an alternative to Erythropoiesis Stimulating Agents for treating anemia associated with CKD. Significantly, the trend toward personalized medicine and the growing awareness pertaining to the benefits of vadadustat have been instrumental in driving its demand.

Vadadustat market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Vadadustat market is projected to grow from $766.3 million in 2024 to $1.51 billion in 2034. This represents a CAGR of 7%, reflecting rising demand across Chronic Kidney Disease Treatment, Therapeutic Areas of Non-Dialysis Dependent Chronic Kidney Disease and Dialysis Anemia Management.
  • Akebia Therapeutics, FibroGen, GlaxoSmithKline are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Japan are the top markets within the Vadadustat market and are expected to observe the growth CAGR of 4.5% to 6.7% between 2024 and 2030.
  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 8.0% to 9.7%.
  • Transition like From EPO based Anemia Treatments to HIFPHI Therapies is expected to add $100.9 million to the Vadadustat market growth by 2030
  • The Vadadustat market is set to add $741 million between 2024 and 2034, with manufacturer targeting Adult & Geriatric Patient Demographics projected to gain a larger market share.
  • With The rising prevalence of anemia, and Advances in renal disease therapeutics, Vadadustat market to expand 97% between 2024 and 2034.
vadadustat market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Vadadustat

Strategic collaborations with hospitals, health clinics, and even other pharmaceutical companies can provide a new growth avenue for Vadadustat. These alliances will not only provide resource sharing but also an extended network for distribution and marketing of the drug.

Growth Opportunities in North America and Asia-Pacific

North America Outlook

North America, likely the most prominent region in the Vadadustat market, has extensively leveraged the drugs benefits for chronic kidney disease patients. This factors into a steady demand, spurred on by research advancements and an aging population. The competitive landscape features heavyweights like Akebia Therapeutics and FibroGen, who have been involved in multiple clinical trials for the drug. However, continuous innovation and evidence-driven strategies are key drivers that are furthering Vadadustats expansive market footprint in the region.

Asia-Pacific Outlook

In the Asia-Pacific region, there is a burgeoning demand for Vadadustat, especially from rapidly developing countries like China and India. Population growth and an increasing prevalence of chronic health conditions fuel this demand. Local generic manufacturers and international pharmaceutical giants are competing fiercely, which has resulted in an escalating need for strategic alliances and partnerships. The main drivers in this region are streamlined regulatory oversight, market-friendly policies, and the evolving healthcare infrastructure, all of which are advancing Vadadustats market penetration.

Market Dynamics and Supply Chain

01

Driver: The Rising Prevalence of Anemia

An increase in the global prevalence of anemia, especially among the aging population, is also driving the market demand for Vadadustat. This novel medication, known for its proven effectiveness in treating anemia associated with Chronic Kidney Disease , is also set to witness stellar growth paths. As the number of anemia patients continues to surge, this would also increase the demand for Vadadustat, a promising solution for anemia management.
Emergence of breakthroughs and advancements in therapeutics of kidney diseases is also another majorthat'saccelerating Vadadustats market prospects. In the quest for effective CKD treatments, Vadadustat, as a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, gains prime focus. The medication showcases an optimal way to stimulate natural erythropoiesis minimizing the risk of the drastic side effects linked with the current treatment options. Intensified research and development in the CKD therapeutics space leading to such novel medicines further underpins the growing demand for Vadadustat.
02

Restraint: Regulatory Hurdles

The market for Vadadustat faces significant challenges in the form of regulatory roadblocks. The molecule has yet to gain approval from regulatory bodies in certain regions around the globe, including the highly coveted U. S. Food and Drug Administration approval. This inevitably restricts the commercial reach of Vadadustat, limiting its potential market growth and revenue generation. Although efforts are continually being made to gain these crucial approvals, the complex and lengthy process can cause significant delays, detrimentally affecting the market dynamics for this innovative therapeutic agent.
03

Opportunity: Targeting Emerging Economies and Scaling Potential with Technological Innovation

Emerging economies present a lucrative prospect due to their growing healthcare infrastructure and increasing rate of chronic diseases, especially related to kidney ailments. Countries like India, Brazil, and South Africa are unventured frontiers where Vadadustat can fill the gap with its highly effective treatment solutions. The expansion to these markets can greatly benefit the overall growth and global footprint of Vadadustat.
The ever-progressing technological landscape presents a significant growth for Vadadustat. With advancements such as AI and ML, the optimization of Vadadustats drug discovery and delivery process can be achieved. This not only speeds up research and development but also ensures precision and efficiency, leading to improved patient outcomes. Incorporating these novel technologies may greatly boost the market position of Vadadustat.
04

Challenge: Competition from Established Treatments

The second major negatively impacting market growth for Vadadustat is the competition it faces from already established treatments. In the therapeutic area of anemia due to chronic kidney disease, where Vadadustat aims to make a significant impact, medicines like Aranesp and Epogen have a firm market presence.

Supply Chain Landscape

1
Raw Material Acquisition

Fujifilm Diosynth Biotechnologies

Cambridge Major Laboratories

2
Production

Akebia Therapeutics

Mitsubishi Tanabe Pharma

3
Distribution & Logistics

Teva Pharmaceutical Industries

Sandoz International

4
End-Users

Pharmaceutical R&D

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Vadadustat in Chronic Kidney Disease Treatment, Therapeutic Areas of Non-Dialysis Dependent Chronic Kidney Disease & Dialysis Anemia Management

Chronic Kidney Disease Treatment

Vadadustat is widely used in the treatment of Chronic Kidney Disease.This is an anemia-associated prescribed medication, primarily focusing on boosting the production of red blood cells. Vadadustat works by inhibiting hypoxia-inducible factor-prolyl hydroxylase, stimulating natural erythropoiesis - the process that produces red blood cells in the human body. Notable players in this market include major pharmaceutical companies like Akebia Therapeutics and Otsuka Pharmaceuticals, recognized for their robust pipeline and consistent innovation in CKD treatment.

Dialysis Anemia Management

Another significant application of Vadadustat is in managing anemia in patients undergoing dialysis. It serves as an alternative to erythropoiesis-stimulating agents , offering the advantage of oral administration and fewer side effects. Vadadustat is primarily beneficial in enhancing the bodys natural response to low oxygen levels and promoting red blood cell production. Top players in this market include FibroGen Inc. and AstraZeneca, commended for their exceptional contribution to dialysis-associated anemia care.

Therapeutic Areas of Non-Dialysis Dependent Chronic Kidney Disease

Vadadustat has shown noteworthy efficacy in the treatment of non-dialysis dependent chronic kidney disease, filling a significant gap in this therapeutic region.

Recent Developments

December 2024

AstraZeneca, a leading pharmaceutical company, announced FDA approval for Vadadustat used in the treatment of anemia associated with Chronic Kidney Disease in non-dialysis dependent patients

October 2024

FibroGen secured patent protection for their novel formulation of Vadadustat, further strengthening their innovative position in the industry

July 2024

Clinical trials of Vadadustat led by Mitsubishi Tanabe Pharma demonstrated remarkable efficacy in increasing haemoglobin levels in dialysis-dependent CKD patients.

Vadadustat has been making innovative strides in the pharmaceutical world, particularly within the chronic kidney disease treatment market. Its recent market developments suggest an optimistic glimpse at the potential avenues this drug can unlock.

Impact of Industry Transitions on the Vadadustat Market

As a core segment of the Pharmaceutical industry, the Vadadustat market develops in line with broader industry shifts. Over recent years, transitions such as From EPO based Anemia Treatments to HIFPHI Therapies and Advancements in Personalized Medicine Personalized Medicine Revolution have redefined priorities across the Pharmaceutical sector, influencing how the Vadadustat market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

From EPO based Anemia Treatments to HIFPHI Therapies

Over recent years, the industry has been witnessing an important transition from Erythropoiesisstimulating agent based treatments to Hypoxia Inducible FactorProlyl Hydroxylase Inhibitor therapies such as Vadadustat. This novel approach in managing anemia related to chronic kidney disease provides potential benefits over traditional treatments such as reduced cardiovascular risks and need for dialysis. The advent of Vadadustat is a prime example of the increasing preference for this cuttingedge, transformative therapy. This industry transition is expected to add $100.9 million in the industry revenue between 2024 and 2030.
02

Advancements in Personalized Medicine Personalized Medicine Revolution

Modern medicine has dramatically advanced towards adopting personalized treatment strategies that take into account individual variability in genes and environment. Vadadustat is an illustrious example of this evolution, considering its novel mechanism of action that mimics the bodys natural response to hypoxia.

Related Reports

Loading related reports...